Over-the-counter non steroidal anti-inflammatory medications: Focus on the management of acute pain

Therapies https://doi.org/10.1016/j.therap.2024.10.061 Ruxandra Burlacu, Venceslas Bourdin, Patrick Blin, Fabrice Camaioni, Béatrice Clairaz, Michel Lantéri-Minet, Françoise Laroche, François Raineri, Serge Perrot, Jean-Paul Stahl, Nicolas H. Thurin, Stéphane Mouly Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) are the second most widely used class of

Sumatriptan-naproxen sodium in migraine: A review

European Journal of Neurology 2024 Sep:31 Suppl 2:e16434. doi: 10.1111/ene.16434. Robyn-Jenia Wilcha, Shazia K Afridi , Piero Barbanti, Hans Christoph Diener, Tim Patrick Jürgens, Michel Lanteri-Minet, Christian Lucas, Jerôme Mawet, Xavier Moisset, Antonio Russo, Simona Sacco, Alexandra J Sinclair, Marja-Liisa Sumelahti , Cristina Tassorelli, Peter J Goadsby  Abstract Background: Varied responses to acute migraine medications

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial

JAMA Neurology 2024 Sep 16:e243043. doi: 10.1001/jamaneurol.2024.3043. Online ahead of print. Stewart J Tepper, David W Dodick, Michel Lanteri-Minet , David Dolezil , Raquel Gil-Gouveia, Christian Lucas, Karolina Piasecka-Stryczynska, Gyöngyi Szabó, Daniel D Mikol, Mahan Chehrenama, Denise E Chou, Yiping Yang, Gabriel Paiva da Silva Lima  Abstract Importance: Patients with chronic migraine and medication

SPIDOL study protocol for the assessment of intrathecal ziconotide antalgic efficacy for severe refractory neuropathic pain due to spinal cord lesions

Trials 2024 Sep 7;25(1):595. doi: 10.1186/s13063-024-08387-0. Andrei Brinzeu, Julien Berthiller, Nathalie Perreton, Fabien Subtil, Caroline Gervaise, Jacques Luaute, Patrick Mertens; SPIDOL Study Group Collaborators  SPIDOL Study Group: Michel Lanteri-Minet, Brigitte Perrouin Verbe, Bechir Jarraya, Philippe Menei, Jimmy Voirin, Jean-Marie Regis, Kevin Buffenoir, Marc Lefort, Denys Fontaine, Jean Luc Barat Abstract Rationale: Central neuropathic pain resulting from spinal

Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study

Cephalalgia 2024 Aug;44(8):3331024241274343.  doi: 10.1177/03331024241274343. Zaza Katsarava, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Aubrey Manack Adams, Karen Carr, Kristina M Fanning, Richard B Lipton Abstract Background: Few studies of migraine have evaluated migraine disability across multiple countries using the same methodology. Methods: This cross-sectional, web-based

Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study

The journal of headache and pain 2024 Aug 19;25(1):134. doi: 10.1186/s10194-024-01834-y. Michel Lanteri-Minet, Elizabeth Leroux, Zaza Katsarava, Richard B Lipton, Fumihiko Sakai, Manjit Matharu, Kristina Fanning, Aubrey Manack Adams, Katherine Sommer, Michael Seminerio, Dawn C Buse Abstract Objective: To assess rates of traversing barriers to care to access optimal clinical outcomes

Somatotopy of the sensory thalamus: inputs from directional deep brain stimulation in pain patients

Annals of Clinical and Translational Neurology 2024 Jun 11.doi: 10.1002/acn3.52067.  Aurelie Leplus, Petru Isan, Anne Balossier, Sarah Mouffok, Anne Donnet, Theodore Papadopoulo, Michel Lanteri-Minet, Jean Regis, Denys Fontaine Abstract Objective: The sensory ventroposterior (VP) thalamic nuclei display a mediolateral somatotopic organization (respectively head, arm, and leg). We studied

Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study

Neurology 2024 May;102(10):e209349.  doi: 10.1212/WNL.0000000000209349. Epub 2024 Apr 26. Uwe Reuter, Peter J Goadsby, Michel D Ferrari, Gabriel Paiva Da Silva Lima, Subhayan Mondal, Jawed Kalim, Fatima Hasan, Shihua Wen, Michal Arkuszewski, Shaloo Pandhi, Tracy Stites, Michel Lanteri-Minet    Abstract Background and objectives: The LIBERTY study assessed the efficacy and safety of erenumab